Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

SPRING, Texas, March 25, 2026 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature, of collaborative studies with Duke University scientists on effects of the company’s anti-cancer compound IRX4204, on human multiple myeloma, a fatal form of bone marrow cancer. The […]


62 h.
Science
ID: 6332549302543546638


Similar News expand_more


Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Technology
Science
Science
Science
Science
Science
Technology
Science
Technology
Science
Technology
Science
Science
Science
Science
Crime
Science
Economics
Science
Technology
Science
Science
Science
Technology
Science
Technology
Science
Science
Science
Economics
Science
Science
Science
Science
Crime
Science
Crime
Science
Popular countries based on strong economic and political relations

Add Watch Country

arrow_drop_down